CRYSTAL LAKE, Ailing.–(BUSINESS WIRE)–AptarGroup, Inc. (NYSE: ATR), a worldwide chief in drug supply, shopper product allotting and lively packaging options, introduced that its Activ-Movie™ know-how was chosen to guard a brand new SARS Fast Antigen check for COVID-19 that just lately acquired Emergency Use Authorization (EUA) from the U.S. Meals and Drug Administration (FDA).
The QuickVue® SARS Antigen check is a point-of-care speedy antigen check developed by Quidel® Company, a number one producer of diagnostic healthcare options, that delivers check leads to 10 minutes. The visually learn check requires no supplemental instrumentation and gives expanded entry to reasonably priced and correct COVID-19 testing that can assist meet the pressing testing wants of the worldwide economic system, together with for these in class techniques and rural areas.
Aptar CSP Applied sciences’ Activ-Movie™ know-how is built-in into the diagnostic equipment to guard in opposition to moisture and different environmental circumstances that might in any other case impression check accuracy. Activ-Movie™ leverages Aptar’s proprietary 3-Section Activ-Polymer™ know-how, which offers a broad spectrum of custom-engineered safety in a wide range of configurations, resembling Activ-Vial™ for housing diagnostics dipsticks and Activ-Tab built-in inside diagnostic cassettes. This materials science-based lively packaging know-how is at the moment used to guard a variety of electrochemical, lateral circulate and molecular diagnostic check kits available on the market at the moment.
“We’re happy to companion with Quidel® Company on this vital diagnostic device and assist carry the QuickVue® SARS Antigen check to the market,” mentioned Stephan B. Tanda, Aptar President and CEO. “Our materials science Activ-Movie™ know-how protects the check strips, serving to to offer fast, dependable outcomes. We’ll proceed to dwell as much as our function and duty to society by offering options that defend vital COVID-19 diagnostic kits, together with allotting options for medicines and shopper merchandise wanted by tens of millions of individuals every day.”
Badre Hammond, Vice President Industrial Operations, Aptar CSP Applied sciences concluded, “As we proceed to navigate by way of the COVID-19 disaster, this game-changing resolution will assist meet the pressing demand for COVID-19 testing in communities world wide. We’re dedicated to leveraging our materials science experience to allow our companions to satisfy the continued want for progressive healthcare options that assist enhance and save lives.”
Aptar is a worldwide chief within the design and manufacturing of a broad vary of drug supply, shopper product allotting and lively materials options. Aptar’s progressive options and companies serve a wide range of finish markets together with pharmaceutical, magnificence, private care, dwelling, meals and beverage. Utilizing insights, design, engineering and science to create allotting, dosing and protecting packaging applied sciences for most of the world’s main manufacturers, Aptar in flip makes a significant distinction within the lives, seems, well being and houses of sufferers and customers world wide. Aptar is headquartered in Crystal Lake, Illinois and has 13,000 devoted staff in 20 nations. For extra data, go to www.aptar.com.
This press launch comprises forward-looking statements. Expressions or future or conditional verbs resembling “will” are meant to determine such forward-looking statements. Ahead-looking statements are made pursuant to the protected harbor provisions of Part 27A of the Securities Act of 1933 and Part 21E of the Securities Alternate Act of 1934 and are primarily based on our beliefs in addition to assumptions made by and data at the moment accessible to us. Accordingly, our precise outcomes might differ materially from these expressed or implied in such forward-looking statements attributable to recognized or unknown dangers and uncertainties that exist in our operations and enterprise surroundings together with, however not restricted to: the profitable integration of acquisitions; the regulatory surroundings; and competitors, together with technological advances. For extra data on these and different dangers and uncertainties, please see our filings with the Securities and Alternate Fee, together with the dialogue below “Danger Components” and “Administration’s Dialogue and Evaluation of Monetary Situation and Outcomes of Operations” in our Type 10-Ks and Type 10-Qs. We undertake no obligation to replace any forward-looking statements, whether or not because of new data, future occasions or in any other case.